165 related articles for article (PubMed ID: 35330907)
1. Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Torres A; Soriano A; Rivolo S; Remak E; Peral C; Kantecki M; Ansari W; Charbonneau C; Hammond J; Grau S; Wilcox M
Clinicoecon Outcomes Res; 2022; 14():149-161. PubMed ID: 35330907
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.
Torres A; Bassetti M; Welte T; Rivolo S; Remak E; Peral C; Charbonneau C; Hammond J; Ansari W; Grau S
J Med Econ; 2020 Feb; 23(2):148-155. PubMed ID: 31686550
[No Abstract] [Full Text] [Related]
3. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.
Stephens JM; Gao X; Patel DA; Verheggen BG; Shelbaya A; Haider S
Clinicoecon Outcomes Res; 2013; 5():447-57. PubMed ID: 24068869
[TBL] [Abstract][Full Text] [Related]
4. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
Wilcox M; Yan JL; Gonzalez PL; Dryden M; Stone GG; Kantecki M
Infect Dis Ther; 2022 Feb; 11(1):217-230. PubMed ID: 34741280
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Huang X; Beresford E; Lodise T; Friedland HD
Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections.
Karve S; Hackett J; Levinson J; Gibson E; Battersby A
J Comp Eff Res; 2016 Jul; 5(4):393-405. PubMed ID: 26946948
[TBL] [Abstract][Full Text] [Related]
7. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals.
Athanasakis K; Petrakis I; Ollandezos M; Tsoulas C; Patel DA; Karampli E; Kyriopoulos J
Infect Dis Ther; 2014 Dec; 3(2):257-68. PubMed ID: 25287947
[TBL] [Abstract][Full Text] [Related]
9. Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.
Sánchez-García M; Hammond J; Yan JL; Kantecki M; Ansari W; Dryden M
Infect Dis Ther; 2020 Sep; 9(3):609-623. PubMed ID: 32607967
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Esposito S; Carrothers TJ; Riccobene T; Stone GG; Kantecki M
Paediatr Drugs; 2021 Nov; 23(6):549-563. PubMed ID: 34462863
[TBL] [Abstract][Full Text] [Related]
11. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
Dryden M; Zhang Y; Wilson D; Iaconis JP; Gonzalez J
J Antimicrob Chemother; 2016 Dec; 71(12):3575-3584. PubMed ID: 27585969
[TBL] [Abstract][Full Text] [Related]
12. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
Cheng K; Pypstra R; Yan JL; Hammond J
J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Scott LJ
Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
[TBL] [Abstract][Full Text] [Related]
14. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
[TBL] [Abstract][Full Text] [Related]
17. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
18. Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe.
Nathwani D; Eckmann C; Lawson W; Solem CT; Corman S; Stephens JM; Macahilig C; Simoneau D; Chambers R; Li JZ; Haider S
BMC Infect Dis; 2014 Sep; 14():476. PubMed ID: 25182029
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
20. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection.
Bally M; Dendukuri N; Sinclair A; Ahern SP; Poisson M; Brophy J
Int J Antimicrob Agents; 2012 Dec; 40(6):479-95. PubMed ID: 23102749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
